|
| | | | | | From Stanford to Startup: Dr. Neal Amin on Building Sculpta Bio
“Neurodegeneration should be treated as a societal emergency.”
That conviction is what led Dr. Neal Amin to leave a 20-year academic career at Stanford and found Sculpta. Rather than accepting the slow pace of progress in Alzheimer’s, Parkinson’s, and ALS, Sculpta is pioneering a “Protein Sculpting” approach that uses alternative RNA splicing to reshape disease-causing proteins in the brain.
In a recent conversation, Neal shared why urgency is central to Sculpta’s mission and how their science challenges the limits of traditional genomic medicine.
READ THE FULL STORY ► |
|
| | | | | Aperture Therapeutics announces first-in-class MMP9 antisense oligonucleotide program for ALS
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Heritable Agriculture announces strategic collaboration with KWS to accelerate genetic improvements in feed crops using AI-driven gene discovery
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Gordian Bio announces research collaboration with Pfizer to accelerate in vivo target discovery in obesity
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | EpiBiologics closes $107M Series B to advance pipeline of novel bispecific antibodies to selectively degrade extracellular protein targets in oncology and immunology
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Cartography Biosciences announces collaboration with Pfizer on the discovery of tumor-selective antigens
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Junevity announces first peer-reviewed research showing single-target repression can reprogram cellular aging
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Dispatch Bio announces FDA clearance of IND application for DISP-10, a first-in-class immunotherapy treatment in solid tumors
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | Marea Therapeutics unveils positive topline phase 1 data for MAR002 in acromegaly; demonstrates potential for best-in-disease efficacy and dosing profile
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
| | | | Interns Mixer with the University of San Francisco
February 6 @ 11am - 1pm
135 Mississippi St, San Francisco
Need extra support in the lab this year? Join us for our upcoming internship matching event with the University of San Francisco at 135 Mississippi Street, San Francisco. Meet and engage with talented biotech students who are ready to contribute fresh perspectives and hands-on support to your team.
REGISTER ► |
|
| Founders at Work: Ridge Bio
February 12 @ 12pm-1pm
1030 Brittan Ave, San Carlos
Ridge Biotechnologies is advancing the next generation of precision therapeutics by combining experiment-informed AI with high-throughput wet-lab methods.
Join us for lunch and hear from Weston Kightlinger, CEO and co-founder of Ridge Biotechnologies as he shares how Ridge Bio is applying machine learning to enzyme and targeted drug design across modalities including ADCs, prodrugs, and catalytic medicines, as well as his journey from academic research to company building.
REGISTER ► |
|
| BrainTech Alliance - Silicon Valley
February 12 @ 4pm-7pm
1030 Brittan Ave, San Carlos
After an incredible year of growth and global gatherings, the BrainTech Alliance will return to the San Francisco Bay Area on Thursday, February 12, 2026, for an evening of ideas, innovation, and impact at the frontier of brain health. If you are interested in applying to attend, please contact anthony.hope@mbcbiolabs.com.
LEARN MORE ► |
|
| Serna Bio Lecture with Andrew Goldberg
February 19 @ 12pm-1pm
Zoom
The Serna Bio lecture series spotlights founders and operators working at the intersection of AI and biology, highlighting the diverse paths shaping this rapidly evolving field.
The second lecture in the series, held via Zoom, features Andrew Goldberg of HealthVerity, who has helped build the company into a leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze patient data at scale.
REGISTER ► |
|
|
|
|
|
|
|
|
|
|
|
| | MEET OUR NEWEST RESIDENTS |
|
| | | Ditto Bio transforms natural proteins into therapeutics for immune disease. Organisms like viruses, ticks, and worms have evolved over millions of years to produce high-affinity immunomodulators that work in humans. We use AI to mine this vast, untapped evolutionary pharmacy and engineer these proteins into novel biologics at unprecedented speed and scale.
Please welcome Dennis Sun, CEO, Adair Borges, CSO, and Emily Weiss, CTO to our 135 Mississippi campus. |
|
| | Form Bio is an AI-driven platform for genetic medicine and genome engineering, integrating AI-based design, synthesis, proprietary data, and lab-in-the-loop validation. The platform enables teams to design, simulate, and optimize genetic constructs at scale to shorten iteration cycles and improve predictability. Since spinning out of Colossal Biosciences in 2022, Form Bio has become a trusted partner to leading drug developers, helping build safer, more manufacturable genetic medicines.
We’re excited to welcome CEO Michelle Chen to our community at 1030 Brittan. |
|
| | Logomix Biotechnology is a cellular system engineering company reimagining drug development as a scalable information science. Its proprietary Geno-Writing™ platform enables complex digital genome designs to be rapidly and precisely written into the human genome, serving as a high-performance execution layer for both internal programs, including Type 1 Diabetes, and global partners across disease areas. Beyond therapeutics, Geno-Writing™ supports Bio-AI by generating high-fidelity iPSC libraries for training foundational and virtual cell models. By closing the design-build-test loop, Logomix provides the engineering engine that helps shift drug discovery from serendipity to an industrial, repeatable process.
A warm welcome to CEO Taiki Ishikura, joining us at 1030 Brittan! |
|
| | Neomera BioLab is addressing the global opioid dependence crisis by developing non-addictive pain therapies for the more than 1.5 billion people worldwide living with chronic pain. Built on over a decade of foundational research at Stanford University, Neomera’s drug discovery platform combines cutting-edge wet-lab biology with proprietary datasets. Purpose-built AI algorithms analyze this data to optimize candidate selection, unlock historically undruggable targets, accelerate development by up to 80%, and reduce discovery costs by up to 90%.
Join us in welcoming Rebecca Miao, CEO and Jimmy Xu, CTO to 1030 Brittan! |
|
| | Sync Bio is creating cell cultures that better mimic the biology of the human body with the goal of improving preclinical drug screening. Sync uses large-scale lab automation to systematically search the space of cell culture configurations.
We’re delighted to welcome CEO Peter Sand to our 953 Indiana site. |
|
| | Weekend is building a flavor protein foundry using next-generation protein design. They're reducing and replacing unhealthy food additives such as sugar, salt, and fat, starting with sugar. Their products are patentable, healthy, delicious, and cheaper than existing solutions at scale.
Welcome CEO Alec Lourenço to 1030 Brittan - we’re glad to have you here!
|
|
|
|
|
|
|
|
|
|
|
|
| | | | |
|
|
|
| |
|
